Among patients who received the first‐generation of EGFR‐TKIs, gefitinib, as first‐line palliative treatment in Quebec, we examined fluctuations in survival by income, education, material deprivation index, immigration, and geographic region, as well as variations in the use and delay of EGFR‐TKI treatment (i.e., use of a second EGFR‐TKI, osimertinib, and delay between the tumor biopsy and first EGFR‐TKI). The gene discussed is EGFR; the disease is neoplasm.